239 related articles for article (PubMed ID: 7687707)
1. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium.
Bethke T; Meyer W; Schmitz W; Scholz H; Wenzlaff H; Armah BI; Brückner R; Raap A
J Cardiovasc Pharmacol; 1993 Jun; 21(6):847-55. PubMed ID: 7687707
[TBL] [Abstract][Full Text] [Related]
2. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart.
Brunkhorst D; v der Leyen H; Meyer W; Nigbur R; Schmidt-Schumacher C; Scholz H
Naunyn Schmiedebergs Arch Pharmacol; 1989 May; 339(5):575-83. PubMed ID: 2549430
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram.
Shahid M; Nicholson CD
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):698-705. PubMed ID: 1710786
[TBL] [Abstract][Full Text] [Related]
5. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers.
Lues I; Beier N; Jonas R; Klockow M; Haeusler G
J Cardiovasc Pharmacol; 1993 Jun; 21(6):883-92. PubMed ID: 7687712
[TBL] [Abstract][Full Text] [Related]
6. Effects of the triazolopyrimidine trapidil on force of contraction, beating frequency and phosphodiesterase I--IV activity in guinea-pig hearts.
Bethke T; Mehl H; Meyer W; Schmitz W; Scholz H; Thomas K; Wenzlaff H
Arzneimittelforschung; 1991 May; 41(5):461-8. PubMed ID: 1716891
[TBL] [Abstract][Full Text] [Related]
7. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts.
Bethke T; Brunkhorst D; von der Leyen H; Meyer W; Nigbur R; Scholz H
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):576-82. PubMed ID: 2457816
[TBL] [Abstract][Full Text] [Related]
9. Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol.
Matsui K; Kiyosue T; Wang JC; Dohi K; Arita M
Cardiovasc Drugs Ther; 1999 Apr; 13(2):105-13. PubMed ID: 10372225
[TBL] [Abstract][Full Text] [Related]
10. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer".
Beier N; Harting J; Jonas R; Klockow M; Lues I; Haeusler G
J Cardiovasc Pharmacol; 1991 Jul; 18(1):17-27. PubMed ID: 1719287
[TBL] [Abstract][Full Text] [Related]
11. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 1st communication: phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart.
Hino M; Sugawara H; Yoshimura A; Ogura A; Yoshioka K; Sakato M; Endoh M
Arzneimittelforschung; 1999 May; 49(5):398-406. PubMed ID: 10367101
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.
Armah BI; Hofferber E; Stenzel W
Arzneimittelforschung; 1988 Sep; 38(9):1287-92. PubMed ID: 2906245
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.
Shahid M; Martorana MG; Cottney JE; Marshall RJ
Br J Pharmacol; 1990 Aug; 100(4):735-42. PubMed ID: 2169938
[TBL] [Abstract][Full Text] [Related]
14. Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.
Berger C; Meyer W; Scholz H; Starbatty J
Arzneimittelforschung; 1985; 35(11):1668-73. PubMed ID: 2418846
[TBL] [Abstract][Full Text] [Related]
15. Positive inotropic activity of 5-amino-6-cyano-1,3-dimethyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrim idine-2,4-dione in cardiac muscle from guinea-pig and man. Part 6: Compounds with positive inotropic activity.
Heber D; Heers C; Ravens U
Pharmazie; 1993 Jul; 48(7):537-41. PubMed ID: 7692456
[TBL] [Abstract][Full Text] [Related]
16. Inotropic and chronotropic profile of MCI-154: comparison with isoproterenol and imazodan in guinea pig cardiac preparations.
Allert JA; Adams HR
J Cardiovasc Pharmacol; 1990 Jul; 16(1):59-67. PubMed ID: 1696667
[TBL] [Abstract][Full Text] [Related]
17. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
18. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
Haikala H; Kaheinen P; Levijoki J; Lindén IB
Cardiovasc Res; 1997 Jun; 34(3):536-46. PubMed ID: 9231037
[TBL] [Abstract][Full Text] [Related]
19. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
[TBL] [Abstract][Full Text] [Related]
20. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
